Search

Your search keyword '"Hepatitis C -- Care and treatment"' showing total 433 results
Start Over Descriptor "Hepatitis C -- Care and treatment" Topic medicine, experimental
433 results on '"Hepatitis C -- Care and treatment"'

1. Researchers at Asklepios Klinik St. Georg Have Reported New Data on Hepatitis (Relink Strategy In Diagnosed-but-untreated Hepatitis C-positive Patients In Germany: Report From a Single Center: Hepatitis C Relink Project Germany)

Subjects
Medical research, Medicine, Experimental, Hepatitis C -- Care and treatment, Physical fitness
Abstract

2024 AUG 10 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Researchers detail new data in Liver Diseases and Conditions - Hepatitis. According […]

Published
2024

2. Recent Findings from University of Toronto Provides New Insights into Hepatitis C Virus (Increasing Treatment Rates for Hepatitis C In Primary Care)

Subjects
Medical research, Medicine, Experimental, Medical personnel -- Training, Primary health care -- Methods, Hepatitis C -- Care and treatment, Health
Abstract

2023 SEP 23 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Research findings on Liver Diseases and Conditions - Hepatitis C Virus are [...]

Published
2023

3. Peoples' Friendship University of Russia (RUDN) Researchers Discuss Findings in Infective Endocarditis (Intractable complicated course of tricuspid valve infective endocarditis due to non-compliance of treatment with clinical guidelines with a ...)

Subjects
Medical research, Medicine, Experimental, Patient compliance, Practice guidelines (Medicine), Infective endocarditis -- Care and treatment, Hepatitis C -- Care and treatment, HIV infection -- Care and treatment, Biotechnology industry, Pharmaceuticals and cosmetics industries, Health
Abstract

2023 SEP 17 (NewsRx) -- By a News Reporter-Staff News Editor at Heart Disease Weekly -- Research findings on infective endocarditis are discussed in a new report. According to news [...]

Published
2023

4. Studies from Iranian Comprehensive Hemophilia Care Center in the Area of Hemophilia Published (Molecular Study of Occult Hepatitis C Infection among Iranian Hemophilia Patients Treated with Direct-acting Antiviral Agents)

Subjects
Medical research, Medicine, Experimental, Antiviral agents, Hepatitis C virus, Infection -- Care and treatment, Hemophilia -- Care and treatment, Hepatitis C -- Care and treatment, Physical fitness, Health
Abstract

2021 MAR 13 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Research findings on hemophilia are discussed in a new report. According to [...]

Published
2021

6. Ain Shams University Researchers Describe Research in HIV/AIDS [Safety and efficacy of directly acting antivirals (sofosbuvir and daclatasvir) in treatment of chronic HCV in HIV-HCV co-infected Egyptian patients]

Subjects
HIV (Viruses) -- Care and treatment, Medical research, Medicine, Experimental, Hepatitis C virus, Infection -- Care and treatment, Hepatitis C -- Care and treatment, Health, Ain Shams University
Abstract

2021 APR 26 (NewsRx) -- By a News Reporter-Staff News Editor at AIDS Weekly -- Fresh data on HIV/AIDS are presented in a new report. According to news reporting from [...]

Published
2021

8. Trio Health Releases Findings from Real-World Studies in Hepatitis C and B Patients

Subjects
Medical research, Medicine, Experimental, Liver, Hepatitis B -- Care and treatment, Hepatitis C -- Care and treatment, Company business management, Business, News, opinion and commentary
Abstract

Four real-world studies presented at the Annual Liver Meeting of the American Association for the Study of Liver Diseases WASHINGTON, Nov. 8, 2019 /PRNewswire/ -- Trio Health, a leading provider [...]

Published
2019

9. Researchers at Military Hospital publish new data on chronic hepatitis

Subjects
Communicable diseases -- Care and treatment, Medical research, Medicine, Experimental, Hepatitis C -- Care and treatment, Health
Abstract

Researchers detail in 'An adult case with onset of celiac disease during chronic hepatitis C antiviral treatment,' new data in chronic hepatitis. According to recent research published in the Romanian [...]

Published
2011

10. Scientists at National Institute of Diabetes and Digestive and Kidney Disease report research in hepatitis C virus

Subjects
Medical research, Medicine, Experimental, Health, Trade and professional associations, Diabetes -- Care and treatment, Hepatitis C virus, Scientists, Kidney diseases -- Care and treatment, Hepatitis C -- Care and treatment, Liver cirrhosis -- Care and treatment, Health
Abstract

'with hepatitis C virus-related cirrhosis are at increased risk for hepatic decompensation and hepatocellular carcinoma (HCC). They also responded less well to standard therapy compared with those without cirrhosis,' scientists [...]

Published
2010

11. Investigators at Tokyo Medical and Dental University release new data on interferon type i

Subjects
Interferon, Communicable diseases -- Care and treatment, Medical research, Medicine, Experimental, Hemoglobin, Biological response modifiers, Universities and colleges, Hepatitis C -- Care and treatment, Health, Tokyo Medical and Dental University
Abstract

New investigation results, 'Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection,' are [...]

Published
2010

12. Sho-saiko-to in Ph I as hepatitis C therapy

Subjects
Liver cirrhosis -- Care and treatment, Hepatitis C -- Care and treatment, Medical research, Medicine, Experimental, Food and beverage industries, Pharmaceuticals and cosmetics industries
Abstract

An estimated five million Americans have been infected with hepatitis C virus (HCV), according to a study published at the Liver Meeting by the American Association for the Study of [...]

Published
2006

13. Probiotic VSL#3 staunches liver dysfunction in liver disease patients

Subjects
Liver cirrhosis -- Care and treatment, Hepatitis C -- Care and treatment, Health, Medical research, Medicine, Experimental
Abstract

Probiotic VSL#3 staunches liver dysfunction in liver disease patients. Researchers in Italy conducted research "to evaluate whether chronic therapy with probiotics affects plasma levels of cytokines and oxidative/nitrosative stress parameters, [...]

Published
2005

14. Therapy halved for some hep C patients

Subjects
Hepatitis C -- Research, Hepatitis C -- Care and treatment, Homeopathy -- Materia medica and therapeutics, Medical research, Medicine, Experimental, Therapeutics, Business, Business, international, Health care industry
Published
2005

15. Blues bad for Hep C

Subjects
Hepatitis C -- Care and treatment, Medical research, Medicine, Experimental, Business, Business, international, Health care industry
Published
2005

16. Event Brief of Gilead Sciences Announces Data for Genotype 1 Null Responder Hepatitis C Patients Enrolled in ELECTRON Study Conference Call - Final

Subjects
The Goldman Sachs Group Inc., Biological products industry, Medical research, Protease inhibitors, Financial analysts, Proteases, Financial markets, Investment banks, Antiviral agents, Hepatitis C virus, Infection -- Care and treatment, Hepatitis C -- Care and treatment, Interferon, Medicine, Experimental, Biological response modifiers, Business
Abstract

PARTICIPANTS . Susan Hubbard, Gilead Sciences Inc, VP, IR . Norbert Bischofberger, Gilead Sciences Inc, EVP of R&D and Chief Scientific Officer . John Milligan, Gilead Sciences Inc, President and [...]

Published
2012

17. Gilead Sciences Announces Data for Genotype 1 Null Responder Hepatitis C Patients Enrolled in ELECTRON Study Conference Call - Final

Subjects
The Goldman Sachs Group Inc., Biological products industry, Interferon, Medical research, Medicine, Experimental, Protease inhibitors, Financial analysts, Proteases, Investment banks, Antiviral agents, Hepatitis C virus, Biological response modifiers, Hepatitis C -- Care and treatment, Business
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by and welcome to Gilead Sciences Conference Call. My name is Stacy and I will be your conference operator for today. [...]

Published
2012

19. Study says hepatitis C will be a rare disease by about 2036

Subjects
Medical research, Medicine, Experimental, Hepatitis C -- Care and treatment, Business, General interest, Business, regional
Abstract

Byline: (Sidebar to main Hepatitis story PITTSBURGH _ Hepatitis C, a major infectious disease in the United States with 180 million cases worldwide, will likely become a rare disease by [...]

Published
2014

20. Skepticism After Egypt Announces Medical Cures

Author

Fahim, Kareem and Sheikh, Mayy El

Subjects
Egypt. Army -- Public relations, Medical research, Medicine, Experimental, AIDS (Disease) -- Care and treatment, Hepatitis C -- Care and treatment, Company public relations, General interest, News, opinion and commentary
Abstract

CAIRO -- At a news conference late last week, an Egyptian Army doctor confidently announced that the country's military had developed a cure for the virus that causes AIDS, as [...]

Published
2014

21. Event Brief of Vertex Pharmaceuticals Incorporated Conference Call to Discuss Phase 3 ILLUMINATE Study Supports 24-Week Telaprevir-Based Therapy - Final

Subjects
Medical research, Medicine, Experimental, Financial analysts, Financial markets, Hepatitis C virus, Biological response modifiers, Clinical trials, Hepatitis C -- Care and treatment, Pharmaceutical industry, Business
Abstract

PARTICIPANTS . Michael Partridge, Vertex Pharmaceuticals Incorporated, Dir. of Corp. Communications . Bob Kauffman, Vertex Pharmaceuticals Incorporated, SVP, Chief Medical Officer . Nancy Wysenski, Vertex Pharmaceuticals Incorporated, EVP, Chief Commercial [...]

Published
2010

22. Event Brief of Vertex Pharmaceuticals Incorporated Strengthens HCV Drug Development Portfolio, Adds Novel Polymerase Inhibitors to Shape New Combinations with Telaprevir Conference Call - Final

Subjects
Vertex Pharmaceuticals Inc. -- Planning, Interferon -- Planning, Protease inhibitors -- Dosage and administration -- Planning, Medical research, Medicine, Experimental, Financial analysts -- Planning, Proteases -- Planning, Financial markets, Drug therapy, Combination, Biological response modifiers, Securities offerings, Hepatitis C -- Care and treatment, Pharmaceutical industry -- Planning, Company business planning, Business
Abstract

PARTICIPANTS . Michael Partridge, Vertex Pharmaceuticals, Inc., Senior Director of Strategic Communications . Kurt Graves, Vertex Pharmaceuticals, Inc., EVP, Chief Commercial Officer, Head of Development . Freda Lewis-Hall, Vertex Pharmaceuticals, [...]

Published
2009

23. Event Brief of Human Genome Sciences Phase 3 Trial in Chronic Hepatitis C Conference Call - Final

Subjects
Novartis AG -- International marketing, Interferon -- International marketing, Biological products industry -- International marketing, Financial analysts, Medical research, Medicine, Experimental, Genomics, Geography, Financial markets, Biological response modifiers, Clinical trials, Hepatitis C -- Care and treatment, Pharmaceutical industry -- International marketing, Business, Pegasys (Medication) -- International marketing
Abstract

PARTICIPANTS . H. Thomas Watkins, Genome Sciences, President, CEO . David Stump, Genome Sciences, EVP, R&D . Geoffrey Porges, Bernstein Research, Analyst . Joseph Schwartz, Leerink Swann, Analyst . Ian [...]

Published
2008

24. Merck's Shortened Hep C Regimens Fall Short of Cure-Rate Goal

Subjects
Merck & Company Inc., Medical research, Medicine, Experimental, Liver diseases -- Care and treatment, Hepatitis C -- Care and treatment, Pharmaceutical industry, Business, Sovaldi (Medication)
Abstract

Byline: Adam Feuerstein To view this article on the web, click here: http://www.thestreet.com/story/12946672/1/mercks-shortened-hep-c-regimens-fall-short-of-cure-rate-goal.html BOSTON (TheStreet) -- Merck's (MRK) initial effort to developer a superior hepatitis C therapy and leapfrog over [...]

Published
2014

25. Janssen Highlights its Hepatitis C Clinical Development Program in Advance of 2014 American Association for the Study of Liver Diseases (AASLD) Annual Meeting

Subjects
Medical research, Medicine, Experimental, Hepatitis C virus, Hepatitis C -- Care and treatment, Business, News, opinion and commentary, Olysio (Medication)
Abstract

-- Studies focused on patients where there is a high unmet need today or anticipated in the near future -- BOSTON, Nov. 7, 2014 /PRNewswire/ -- Janssen R&D Ireland (Janssen) [...]

Published
2014

26. Medivir: An all-oral phase IIa study combining Simeprevir, TMC647055 and JNJ56914845 in hepatitis C patients to be initiated

Subjects
Medivir AB, Medical research, Medicine, Experimental, Hepatitis C virus, Hepatitis C -- Care and treatment, Pharmaceutical industry, Business, Business, international
Abstract

STOCKHOLM -- Medivir AB (STO:MVIR-B) (OMX: MVIR), announces the initiation of a phase IIa trial in chronic genotype 1 hepatitis C infected patients to evaluate the efficacy, safety and tolerability [...]

Published
2013

27. Medivir: Primary efficacy and safety findings from phase III study of Simeprevir in treatment-experienced patients demonstrate sustained virologic response

Subjects
Medivir AB, Biological products industry, Interferon, Protease inhibitors, Medical research, Medicine, Experimental, Proteases, Biological response modifiers, Liver diseases -- Care and treatment, Hepatitis C -- Care and treatment, Pharmaceutical industry, Business, Business, international
Abstract

STOCKHOLM -- Regulatory News: Medivir AB (OMX:MVIR)(STO:MVIR-B) reports that its partner Janssen R&D Ireland (Janssen) today announced primary efficacy and safety results from the global phase III PROMISE study. Results [...]

Published
2013

28. Abbott Announces Phase 3 Hepatitis C Program Details

Subjects
Medical research, Medicine, Experimental, Antiviral agents -- Product development, Hepatitis C virus, Clinical trials, Hepatitis C -- Care and treatment, Business, News, opinion and commentary
Abstract

- Interferon-free Hepatitis C Regimens will be Studied in Broad Patient Populations across Multiple Countries ABBOTT PARK, Ill., Nov. 13, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today released details on [...]

Published
2012

29. Milk Thistle Extract Doesn't Help Liver Patients, Trial Finds

Subjects
Medical research, Medicine, Experimental, Milk, Dairy industry, Liver, Liver diseases -- Care and treatment, Hepatitis C -- Care and treatment, Business, international, News, opinion and commentary
Abstract

Many patients with chronic hepatitis C infections turn to botanical supplements when traditional medicine fails them. But one of those alternative medicines, a product called silymarin derived from the milk [...]

Published
2012

30. SUSTAINED VIRAL RESPONSE ACHIEVED IN 83% OF HEPATITIS C PATIENTS

Subjects
Boehringer Ingelheim GmbH, Technological innovations, Protease inhibitors, Medical research, Medicine, Experimental, Proteases, Hepatitis C virus, Health care industry, Hepatitis C -- Care and treatment, Pharmaceutical industry, Health care industry, Business, general
Abstract

(Full text of a statement. Contact details below.) (BW)(BOEHRINGER-INGELHEIM) Sustained viral response achieved in 83 per cent of hepatitis C infected patients with new HCV protease inhibitor from Boehringer Ingelheim [...]

Published
2011

31. Tibotec Advances Global Clinical Research Program For TMC435 in HCV

Subjects
Medical research, Medicine, Experimental, Hepatitis C virus, Clinical trials, Hepatitis C -- Care and treatment, General interest, News, opinion and commentary
Abstract

Mar 30, 2011 (M2 PRESSWIRE via COMTEX) -- Tibotec Pharmaceuticals announced today that four abstracts reporting research findings with TMC435, the company's investigational hepatitis C protease inhibitor, have been accepted [...]

Published
2011

32. Scripps Pioneers Individualized Medicine by Offering Genetic Testing to Hepatitis C Patients

Subjects
Medical research, Medicine, Experimental, Biological response modifiers, Hepatitis C -- Care and treatment, Genetic screening, Banking, finance and accounting industries, Business
Abstract

Byline: Staff SAN DIEGO, Feb 25, 2011 (GlobeNewswire via COMTEX) -- Scripps Health is one of the first health systems in the United States to offer genetic testing as part [...]

Published
2011

33. Anadys Pharmaceuticals initiates Phase IIb study of Ana598 in HCV patients

Subjects
United States. Food and Drug Administration, Anadys Pharmaceuticals Inc. -- Product development, Medical research, Medicine, Experimental, Antiviral agents -- Product development, Hepatitis C virus, Biological response modifiers, Hepatitis C -- Care and treatment, Pharmaceutical industry -- Product development, Business, Chemicals, plastics and rubber industries
Abstract

Anadys Pharmaceuticals Inc (Anadys) announced that it had initiated the planned Phase IIb study of Ana598 in combination with pegylated interferon and ribavirin. The protocol for the study had been [...]

Published
2011

34. Pharmasset Initiates Dosing in a Combination Study of PSI-7977 and PSI-938 for Chronic Hepatitis C

Subjects
Roche Holding AG, Medical research, Medicine, Experimental, Hepatitis C virus, Pyrimidines, Hepatitis C -- Care and treatment, Pharmaceutical industry, Business, News, opinion and commentary
Abstract

- Phase 1 combination study of a pyrimidine (PSI-7977) and purine (PSI-938) nucleotide analog in patients with chronic hepatitis C - Interim data expected in first quarter of 2011 PRINCETON, [...]

Published
2010

35. Medivir announces positive 24-week interim data of TMC435 from the ASPIRE study (C206). [2 tables in original article]

Subjects
Medivir AB, Medical research, Medicine, Experimental, Hepatitis C -- Care and treatment, Pharmaceutical industry, Business, Chemicals, plastics and rubber industries
Abstract

Medivir AB announces positive top-line 24-week interim data from the Phase IIb ASPIRE (C206) study of TMC435 in treatment-experienced hepatitis C patients. The results demonstrate the potent and consistent antiviral [...]

Published
2010

36. Medivir AB announces positive 24-week interim data of TMC435 from the ASPIRE study

Subjects
Medivir AB, Medical research, Medicine, Experimental, Hepatitis C -- Care and treatment, Pharmaceutical industry, Business, Chemicals, plastics and rubber industries
Abstract

Medivir AB, the emerging research-based speciality pharmaceutical company focused on infectious diseases, announces positive top-line 24-week interim data from the Phase IIb ASPIRE study of TMC435 in treatment-experienced hepatitis C [...]

Published
2010

37. Vertex Pharmaceuticals Announces Start of a Phase 3b Study of Twice-Daily Telaprevir in People Not Treated Previously for Hepatitis C

Subjects
Vertex Pharmaceuticals Inc. -- Product development, Protease inhibitors -- Product development, Medical research, Medicine, Experimental, Proteases -- Product development, Hepatitis C virus, Hepatitis C -- Care and treatment, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

- First Phase 3 study to evaluate twice-daily (BID) dosing of a protease inhibitor for hepatitis C - - All patients will receive telaprevir-based combination therapy - CAMBRIDGE, Mass. -- [...]

Published
2010

38. NEW HOPE FOR TREATING HEPATITIS C: TELAPREVIR : SAINT LOUIS UNIVERSITY : SLU

Subjects
Protease inhibitors, Medical research, Medicine, Experimental, Proteases, Universities and colleges, Hepatitis C -- Care and treatment, News, opinion and commentary
Abstract

St. Louis, MO -- The following information was released by St. Louis University: New Hope for Treating Hepatitis C: Telaprevir Findings Bode Well for Hard-to-Treat Patients A study co-authored by [...]

Published
2010

39. NVHR: New Data Finding Fewer than 1 in 5 Hepatitis C Patients Receiving Antiviral Therapy is 'Wake-Up Call' for Washington

Subjects
Medical research, Medicine, Experimental, Antiviral agents, Hepatitis C -- Care and treatment, Business, Science and technology
Abstract

WASHINGTON, Nov. 24 /PRNewswire-USNewswire/ -- New peer-reviewed data finding that fewer than one-fifth of the nearly 4 million Americans infected with chronic hepatitis C virus have received anti-viral therapy in [...]

Published
2009

40. More than 80% of Hepatitis C Patients Treated in Study C208 Achieved an SVR with Telaprevir-Based Regimens

Subjects
Vertex Pharmaceuticals Inc., Hepatitis C -- Care and treatment, Pharmaceutical industry, Medical research, Medicine, Experimental, Business, Business, international
Abstract

* 83% SVR achieved with twice-daily regimen of telaprevir dosed with PEGASYS and ribavirin * Results highlight the use of response-guided therapy in managing treatment outcomes * Similar safety and [...]

Published
2009

41. Medtronic Initiates Phase II Hepatitis C Clinical Study 'COPE-HCV' to Determine Tolerability and Safety of Continuous Interferon Infusion for Patients with HCV

Subjects
Interferon -- Product development, Medical research, Medicine, Experimental, Biological response modifiers, Clinical trials, Hepatitis C -- Care and treatment, Business, Business, international
Abstract

Medtronic Paradigm® Pump Infusion System and CareLink™ Clinical Monitoring System Used to Study the Continuous Delivery of INTRON A in Previously Untreated Genotype 1 Patients MINNEAPOLIS -- Medtronic, Inc. (NYSE: [...]

Published
2009

42. OctoPlus' Licensee Biolex Completes Patient Enrollment in Phase IIb Study With Locteron

Subjects
Medical research, Medicine, Experimental, Interferon alpha, Biological response modifiers, Clinical trials, Hepatitis C -- Care and treatment
Abstract

LEIDEN, THE NETHERLANDS, Jun 29, 2009 (MARKETWIRE via COMTEX) -- OctoPlus N.V. ('OctoPlus') (Euronext: OCTO) announces today that its licensee Biolex Therapeutics (see separate Biolex press release on www.biolex.com) has […]

Published
2009

43. OctoPlus' licensee Biolex completes patient enrollment in Phase IIb study with Locteron

Subjects
Medical research, Medicine, Experimental, Drugs -- Vehicles, Interferon alpha, Biological response modifiers, Clinical trials, Hepatitis C -- Care and treatment, Drug delivery systems -- Product development
Abstract

LEIDEN, NETHERLANDS, Jun 29, 2009 (MARKETWIRE via COMTEX) -- OctoPlus N.V. ('OctoPlus') (Euronext: OCTO) announces today that its licensee Biolex Therapeutics (see separate Biolex press release on www.biolex.com) has completed […]

Published
2009

44. OctoPlus' Licensee Biolex Commences Phase IIb Study With Locteron

Subjects
Medical research, Medicine, Experimental, Drugs -- Vehicles, Interferon alpha, Biological response modifiers, Clinical trials, Hepatitis C -- Care and treatment, Drug delivery systems
Abstract

LEIDEN, THE NETHERLANDS, Apr 20, 2009 (MARKET WIRE via COMTEX) -- OctoPlus N.V. ('OctoPlus' or 'the Company') (EURONEXT: OCTO) announces today that its licensee Biolex Therapeutics (see separate Biolex press […]

Published
2009

45. OctoPlus' licensee Biolex commences Phase IIb study with Locteron

Subjects
Medical research, Medicine, Experimental, Interferon alpha, Biological response modifiers, Clinical trials, Hepatitis C -- Care and treatment
Abstract

LEIDEN, NETHERLANDS, Apr 20, 2009 (MARKET WIRE via COMTEX) -- OctoPlus N.V. ('OctoPlus' or 'the Company') (Euronext: OCTO) announces today that its licensee Biolex Therapeutics (see separate Biolex press release […]

Published
2009

46. New Clinical Data Support Broad Profile for Telaprevir in Patients with Genotype 1 Hepatitis C Virus (HCV) Infection

Subjects
Proteases -- Product development, Protease inhibitors -- Product development, Protease inhibitors -- Complications and side effects, Hepatitis C -- Care and treatment, Hepatitis C -- Complications and side effects, Clinical trials, Medical research, Medicine, Experimental, Business, Business, international
Abstract

-- PROVE 3 data show 52% SVR12 in HCV treatment-failure patients with 24-week treatment duration -- -- PROVE 2 final results confirm 69% SVR in HCV treatment-naive patients with 24-week [...]

Published
2008

47. Tibotec Begins Enrollment for Phase III Study of Telaprevir, an Investigational Agent, in HCV Patients Who Failed Prior Treatment

Subjects
Protease inhibitors -- Product development, Medical research, Medicine, Experimental, Proteases -- Product development, Clinical trials, Hepatitis C -- Care and treatment, Business, Science and technology, Care and treatment, Product development
Abstract

REALIZE is the first phase III study to evaluate a specifically targeted antiviral therapy for hepatitis C (STAT-C) across a full range of HCV-patients who failed prior treatment to current [...]

Published
2008

48. Vertex Pharmaceuticals to Begin Phase 3 Development of Telaprevir, Investigational Hepatitis C Protease Inhibitor

Subjects
Vertex Pharmaceuticals Inc. -- Product development, Pharmaceutical industry -- Product development, Hepatitis C -- Care and treatment, Proteases -- Product development, Medical research, Medicine, Experimental, Business, Business, international
Abstract

* Primary Phase 3 trial will focus on studying 24-week telaprevir-based regimens * Vertex plans concurrent second study to support registration * Final data from both trials anticipated in mid- [...]

Published
2008

49. Studies from M. Stepanova and Co-Researchers in the Area of Chronic Hepatitis Reported (Patients' preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens) (Patients' ...)

Subjects
Medical research, Medicine, Experimental, Hepatitis C -- Care and treatment, Health
Abstract

By a News Reporter-Staff News Editor at Hepatitis Weekly -- Research findings on Liver Diseases and Conditions are discussed in a new report. According to news originating from Falls Church, [...]

Published
2014

50. Two Studies in The New England Journal of Medicine Demonstrated That PROMACTA (TM) (Eltrombopag) Significantly Raised Platelet Counts in Patients With Chronic Hepatitis C-Associated Thrombocytopenia and Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Subjects
Medical research, Medicine, Experimental, Hepatitis C -- Care and treatment, Thrombocytopenic purpura -- Care and treatment, Business, Science and technology, Care and treatment
Abstract

PHILADELPHIA, Nov. 28 /PRNewswire-USNewswire/ -- Data from Phase II studies published today in the New England Journal of Medicine (NEJM) report that GlaxoSmithKline's (GSK) investigational compound PROMACTA (TM) (eltrombopag) significantly [...]

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results